Mind-body therapies like meditation, psychotherapy, and deep breathing may help reduce stress levels, potentially reducing ...

P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

NDAQ:KYMR) Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral ...

Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...

Despite positive preliminary data from its early stage study of treating hives, Jasper Therapeutics Inc. saw its stock drop dramatically on Jan. 8. Results were from the ongoing phase Ib/IIa study of ...